Risk of Metabolic Adaptation After Weight Loss
- Conditions
- ObesityWeight Loss
- Interventions
- Other: phentermine-topiramate combined with lifestyle interventionOther: lifestyle intervention with meal replacement program
- Registration Number
- NCT05139420
- Lead Sponsor
- Medical College of Wisconsin
- Brief Summary
This study aims at identifying the neurohormonal biomarkers that characterize individuals at risk of greater metabolic adaptation to weight loss, a disproportionate decline in resting metabolic rate during and after weight loss.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- SUSPENDED
- Sex
- All
- Target Recruitment
- 60
BMI > or = 30 any ethnicity
weight > or = 400 lbs.
diabetes (type 2 or type 1)
hypertension
heart disease
kidney disease
liver disease
active cancer
post solid organ or bone marrow transplant
HIV/AIDS
pregnancy
breastfeeding
current smoker
current recreational drug use
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description lifestyle intervention plus phentermine-topiramate phentermine-topiramate combined with lifestyle intervention Participants will be enrolled in a weight loss program based on lifestyle changes and the use of phentermine-topiramate to aid with weight loss lifestyle intervention lifestyle intervention with meal replacement program Participants will be enrolled in a weight loss program based on lifestyle changes. They will be given a 6-month subscription to a calorie-reduced meal replacement program that also offers lifestyle coaching.
- Primary Outcome Measures
Name Time Method change in measured and predicted resting metabolic rate during and after weight loss 18 months resting metabolic rate will be measured by indirect calorimetry every 2 months for 6 months, then every 6 months for an additional 12 month. Predicted resting metabolic rate will be calculated with a mathematical formula at the same time points
- Secondary Outcome Measures
Name Time Method change in circulating thyroid hormones during and after weight loss 18 months blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months
change in circulating AgRP during and after weight loss 18 months blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months
change in heart rate variability during and after weight loss 18 months blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months
change in circulating PYY during and after weight loss 18 months blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months
change in circulating leptin during and after weight loss 18 months blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months
change in circulating GLP-1 during and after weight loss 18 months blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months
change in 24h urine catecholamines during and after weight loss 18 months urine will be assayed for these hormones every 2 months for 6 months, then every 6 months for an additional 12 months
Trial Locations
- Locations (1)
Medical College of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States